218 related articles for article (PubMed ID: 29998369)
1. Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.
Meng Y; Zhang M; Zhao X; Cheng Y; Jia R; Wang Y; Sun X
Clin Rheumatol; 2018 Oct; 37(10):2707-2714. PubMed ID: 29998369
[TBL] [Abstract][Full Text] [Related]
2. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
Becker-Merok A; Nikolaisen C; Nossent HC
Lupus; 2006; 15(9):570-6. PubMed ID: 17080911
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.
Atta MS; Lim KL; Ala'deen DA; Powell RJ; Todd I
Ann Rheum Dis; 1995 Feb; 54(2):117-24. PubMed ID: 7702398
[TBL] [Abstract][Full Text] [Related]
4. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?
de Carvalho JF; Borba EF; Viana VS; Bueno C; Leon EP; Bonfá E
Arthritis Rheum; 2004 Nov; 50(11):3610-5. PubMed ID: 15529371
[TBL] [Abstract][Full Text] [Related]
5. Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders.
Saxena R; Sturfelt G; Nived O; Wieslander J
Ann Rheum Dis; 1994 Oct; 53(10):659-65. PubMed ID: 7979578
[TBL] [Abstract][Full Text] [Related]
6. [The autoantibody profile and disease activity in patients with systemic lupus erythematosus].
Horák P; Hermanová Z; Faltýnek L; Pospísil Z; Scudla V
Vnitr Lek; 1997 Oct; 43(10):639-44. PubMed ID: 9601876
[TBL] [Abstract][Full Text] [Related]
7. The homogeneous multiplexed system--a new method for autoantibody profile in systemic lupus erythematosus.
Zandman-Goddard G; Gilburd B; Shovman O; Blank M; Berdichevski S; Langevitz P; Shoenfeld Y
Clin Dev Immunol; 2005 Jun; 12(2):107-11. PubMed ID: 16050141
[TBL] [Abstract][Full Text] [Related]
8. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
Lim KL; Jones AC; Brown NS; Powell RJ
Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
10. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia.
Leaños A; Pascoe D; Fraga A; Blanco-Favela F
Lupus; 1998; 7(6):398-403. PubMed ID: 9736323
[TBL] [Abstract][Full Text] [Related]
11. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
12. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus.
Chun HY; Chung JW; Kim HA; Yun JM; Jeon JY; Ye YM; Kim SH; Park HS; Suh CH
J Clin Immunol; 2007 Sep; 27(5):461-6. PubMed ID: 17587156
[TBL] [Abstract][Full Text] [Related]
13. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
14. Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals.
Gutiérrez MA; Molina JF; Jara LJ; García C; Gutiérrez-Ureña S; Cuéllar ML; Gharavi A; Espinoza LR
Int Arch Allergy Immunol; 1996 Mar; 109(3):229-35. PubMed ID: 8620091
[TBL] [Abstract][Full Text] [Related]
15. Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus.
Hanly JG; Thompson K; McCurdy G; Fougere L; Theriault C; Wilton K
J Immunol Methods; 2010 Jan; 352(1-2):147-52. PubMed ID: 19836394
[TBL] [Abstract][Full Text] [Related]
16. Anti-prolactin autoantibodies in paediatric systemic lupus erythematosus patients.
Blanco-Favela F; Quintal MaG ; Chavez-Rueda AK; Leaños-Miranda A; Berron-Peres R; Baca-Ruiz V; Lavalle-Montalvo C
Lupus; 2001; 10(11):803-8. PubMed ID: 11789490
[TBL] [Abstract][Full Text] [Related]
17. Use of a new fluorescence immunoassay to detect anti-dsDNA antibodies is more correlated with disease activity and complement than the ELISA method in SLE patients.
Chen CY; Tseng HM; Chen LC; Tsao CH; Kuo ML; Ou LS; Huang JL
Lupus; 2003; 12(4):266-73. PubMed ID: 12729049
[TBL] [Abstract][Full Text] [Related]
18. Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus.
Sjöwall C; Ernerudh J; Bengtsson AA; Sturfelt G; Skogh T
J Autoimmun; 2004 Jun; 22(4):315-23. PubMed ID: 15120755
[TBL] [Abstract][Full Text] [Related]
19. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
20. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies.
Pradhan VD; Patwardhan MM; Ghosh K
Indian J Dermatol Venereol Leprol; 2010; 76(2):145-9. PubMed ID: 20228543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
